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Introduction: Epidermal growth factor receptor (EGFR) gene in-
tron 1 contains a polymorphic single sequence dinucleotide repeat
(CA)n whose length has been found to inversely correlate with
transcriptional activity. This study was designed to assess the role of
(CA)n polymorphism in predicting the outcome of gefitinib treat-
ment in advanced non-small cell lung cancer (NSCLC).
Methods: Blood and tumor tissue from 58 patients with advanced
NSCLC submitted to gefitinib were collected. EGFR intron 1 gene
polymorphism, along with EGFR gene mutation, gene copy number
and immunohistochemistry expression were determined. Moreover,
a panel of lung cancer cell lines characterized for EGFR intron 1
polymorphism was also studied.
Results: EGFR intron 1 polymorphism showed a statistically sig-
nificant correlation with the gefitinib response (response rate 25
versus 0%, for patients with a (CA)16 and with a (CA)else genotype,
respectively; p  0.044). Patients with a (CA)16 genotype had a
longer survival compared with those with a (CA)else genotype (11.4
versus 4.8 months, respectively; p  0.037). In addition, cell lines
lacking the (CA)16 allele showed a statistically significant higher
IC50 compared with cell lines bearing at least one (CA)16 allele (p 
0.003).
Conclusions: This study supports a potential role of EGFR intron 1
polymorphism in predicting the outcome of gefitinib treatment in
advanced NSCLC.
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Gefitinib and erlotinib, small molecules reversibly bindingthe ATP pocket in the epidermal growth factor recep-
tor (EGFR) intracellular tyrosine kinase domain, represent
a new reality in the treatment of non-small cell lung cancer
(NSCLC). Nevertheless, it appears that the greatest benefit
obtained with these EGFR tyrosine kinase inhibitors (TKIs) is
confined to some patient subgroups. Patients with the highest
probability of response appear to be those of female sex,
never-smokers, with adenocarcinoma histology and, particu-
larly, with bronchiolo-alveolar carcinoma.1
Although clinical characteristics could be useful for the
identification of candidate to EGFR TKIs, selection of pa-
tients should ideally rely on biologic tumor characteristics.2
Specific mutations in the tyrosine kinase domain (exons
18–21) of the EGFR gene have been found to account for the
increased sensitivity to gefitinib or erlotinib.3 Recent trials
have suggested that EGFR gene copy number and EGFR
expression can be used to predict which patients are more
likely to respond to EGFR TKIs.4
Moreover, Dziadziuszko et al.5 demonstrated that EGFR
mRNA expression in paraffin-embedded NSCLC specimens is
also a predictive biomarker of gefitinib response. Transcription
of the EGFR gene is regulated by two enhancer elements. In
particular, the one located in intron 1, downstream of the
transcription initiation site, has an important regulatory func-
tion.6 It contains a characteristic simple sequence repeat of CA
dinucleotides, whose length exhibits interethnic differences7–9
and has been shown to correlate inversely with EGFR gene
transcription, differentially modifying DNA conformation
after binding of transcriptor factors.10–12 This sequence con-
tains a number of (CA)n repeats ranging from 9 to 2313,14 and
alleles with 16 CA repeats showed the highest frequency
(43%) in Caucasians.7
Preclinical studies in head and neck cancer cell lines
suggested that EGFR gene intron 1 polymorphism may cor-
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relate with response to EGFR TKIs.15 To investigate this
correlation in the clinic, we evaluated the allele status and
length of the intron 1 polymorphic region in NSCLC patients
treated with gefitinib within an Expanded Access Program.
Since this region is not generally somatically mutated15 and
to overcome the limited availability of tumor specimens in
the clinical practice, EGFR (CA)n status was characterized in
DNA obtained from whole blood. When sufficient tumor tissue
was available, the other known predictive factors (EGFR
expression, gene mutations and gene copy number) were also
investigated and correlated with response and survival.
To further investigate the correlation between the length
of EGFR (CA)n repeats and gefitinib response, we studied in
vitro growth inhibition in a panel of NSCLC cell lines with
different EGFR intron 1 polymorphisms.
PATIENTS AND METHODS
Patients
Patients, enrolled prospectively in this study, were
included in Iressa Expanded Access Program and in our
previous trial,16 conducted at Parma University Hospital and
the National Institute for Cancer Research in Genova. This
study was approved by the institutional ethical review board
and written informed consent was obtained from each patient
before enrollment, together with the Expanded Access Study
consent form.
Eligibility criteria included histologically confirmed
NSCLC with measurable, locally advanced or metastatic dis-
ease, progressing or relapsing after at least one line of standard
chemotherapy. Patients had performance status ranging from
grade 0 to 2, according to Eastern Cooperative Oncology
Group. Patients received gefitinib (250 mg/d) and were eval-
uated for response according to the Response Evaluation
Criteria in Solid Tumors criteria. Tumor response was as-
sessed by computed tomography scan after 2 months of
treatment. Patients obtaining complete response, partial re-
sponse or stable disease remained on therapy until disease
progression or excessive toxicity with tumor reassessment
every 2 months. Toxicity, assessed monthly by clinical ex-
amination and blood counts and chemistry, was evaluated
according to National Cancer Institute-Common Toxicity
Criteria version 2.0. Survival was calculated from the date of
therapy initiation to the date of death or to the date of last
contact.
An additional cohort of advanced NSCLC patients,
who did not receive gefitinib treatment but only standard
chemotherapy and well balanced for each of the clinical
characteristics (age, gender, histology, performance status
and stage of disease) with the patients treated with gefitinib,
was sought within the clinical data base and blood bank of the
same institutions to serve as control group.
Genotype Characterization
Genomic DNA was isolated from whole venous blood
samples and amplified as previously described.17 Fluorescent-
labeled polymerase chain reaction products were run on an
automated capillary electrophoresis-based DNA sequencer
ABI PRISM 310 Genetic Analyzer (Applied Biosystems) and
were analyzed using Genescan to determine the sizes of
repeated length.
EGFR Gene Mutational Analysis
Genomic DNA was extracted from microdissected tu-
mor cells of formalin-fixed paraffin-embedded tissue sec-
tions. Amplifications of exons 18 through 21 of EGFR were
performed using nested primers as published.18–20 Polymer-
ase chain reaction fragments were sequenced and analyzed in
both forward and reverse directions and mutations were
verified by three independent amplifications.
EGFR Gene Copy Number by Fluorescence In
Situ Hybridization
EGFR gene copy number per cell was investigated on
formalin-fixed paraffin-embedded specimens using LSI
EGFR Spectrum orange/CEP 7 Spectrum green probe set
(Vysis, Downers Grove, IL). The fluorescence in situ hybrid-
ization (FISH) protocol and sample classification is described
in details elsewhere.21 The FISH analysis was performed
independently by two authors (C.B. and G.R.) who were
blinded to the patients’ clinical characteristics and all other
molecular variables.
EGFR, p-EGFR, p-MAPK and p-AKT
Immunohistochemistry
Paraffin-embedded tissue sections from tumor speci-
mens obtained at the time of primary diagnosis were analyzed
for EGFR, p-EGFR, p-MAPK and p-AKT. Protein expres-
sion was evaluated by immunohistochemistry (IHC) using
methods and assessment criteria described elsewhere.16,22
The immunostaining for EGFR, p-EGFR, p-MAPK and
p-AKT expression was classified into two categories: “neg-
ative” (including negative samples and samples with 10%
positive cells, but with weak staining [1]) and “positive” (if
more than 10% of the tumor cells stained moderately [2],
and if more than 10% of the cells stained strongly [3]).16
IHC was assessed by two observers on all sections, blinded to
clinical and other biologic results. If discrepancies occurred,
a consensus score was made by the two readers after discus-
sion of the slide. The IHC data and also the results of EGFR
gene mutation and FISH analyses have been reported in a
previous publication.16
Cell Cultures and MTT Assay
The human NSCLC cell lines A549, H460, H1650,
H1299, Calu-3, SKMES-1, SKLU-1 were cultured as recom-
mended. Cell viability was assessed after 3 days of gefitinib
treatment by tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), Sigma, Dorset, UK]
assay as previously described.23 Representative results of at
least three independent experiments were used for evaluation
of dose-response curves, calculated from experimental points
using single or double Hill functions (Origin 6.0 Software,
Microcal).24 Concentration that inhibits 50% (IC50) (e.g., the
point at which viability is 50%) was extrapolated from the
dose-response curves.23
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Statistical Analysis
The association between clinical and biologic charac-
teristics was tested using the standard 2 test or the Fisher
exact test. The impact of clinical and biologic characteristics
on response rate was analyzed using multivariate logistic
regression. Overall survival was defined as the time between
study registration and death, whatever the cause. Estimates of
overall survival were calculated according to the Kaplan-
Meier method. Comparisons of estimated survival curves
were performed by means of the log-rank test. Finally, to
investigate the joint effect of the clinical and biologic char-
acteristics on overall survival, a Cox proportional hazard
model was fitted to the data.
To assess for possible evolutionary changes occurring
in the EGFR (CA)n repeat polymorphism, Hardy-Weinberg
analysis was performed by matching allele frequencies in the
observed individuals to those expected under Hardy-Wein-
berg Equilibrium. Genotypes were dichotomized as EGFR
(CA)16, including at least one (CA)16 allele, and EGFR
(CA)else, lacking the EGFR (CA)16 allele, and compared using
a 2 test goodness-of-fit test.
Differences between mean IC50 values in cell lines
classified as bearing a (CA)16 or a (CA)else EGFR intron 1
polymorphism were assessed by unpaired Student t test.
RESULTS
Patients Characteristics
A total of 58 previously treated patients with advanced
NSCLC were prospectively enrolled in this study. The main
characteristics of the patients are shown in Table 1.
For the entire group, the objective response rate was
15% (two complete and seven partial responses), the disease
control rate (complete response  partial response  stable
disease) was 38% and overall median survival was 6 months.
Patients with an objective response had a median survival of
18.5 months versus 5.1 month of nonresponders (p  0.014).
Female sex, never smoking status and adenocarcinoma
histology were associated with a higher probability of re-
sponse to gefitinib treatment (Table 2). During treatment,
toxicity of any grade and type was noted in 29 patients (50%)
and consisted mainly of skin rash and gastro-intestinal disor-
ders; in particular, 24 patients (41%) developed an acne-like
rash. We found a positive predictive role for general toxicity
(p  0.025), but not for skin toxicity (p  0.142) (Table 2).
In terms of disease control, both general toxicity (p  0.003)
and skin toxicity (p  0.013) evidenced a statistically signif-
icant role in predicting gefitinib activity. Moreover, patients
who developed toxicity during gefitinib treatment had a
statistically significant improvement in survival (p  0.002)
(Table 2).
EGFR Intron 1 Polymorphism
EGFR intron 1 polymorphism could be characterized
in 51 patients (for seven patients the blood sample were
not available). Alleles ranging within 14 to 21 dinucleotides
were found, with the most frequent being (CA)16 and (CA)18.
Heterozygosity was observed in 64.7% (33/51) of patients
and in 69.7% (23/33) of these the shorter allele consisted of
(CA)16 repeats. Seventeen different (CA)n genotypes were found
and the most common were 16 to 16 (29.4%) and 16 to 18
(13.7%). Allele and genotype frequencies, reported in Table 3,
were in agreement with other published Caucasians series.7,8
Among the 15 patients with a genotype lacking the
(CA)16 allele, 14 had at least one long allele (17 dinucle-
otides). To evaluate the predictive value of EGFR intron 1
polymorphism, we divided patients into two subgroups: 36
(70.6%) bearing at least one (CA)16 allele [(CA)16 genotype]
and 15 (29.4%) lacking the (CA)16 allele [(CA)else genotype].
According to this dichotomy, genotype frequencies were
not significantly different from what expected on the basis of the
Hardy-Weinberg Equilibrium (2  0.956, p  0.620).
Eighty percent of patients carrying the (CA)16 allele
were adenocarcinoma. All mutated patients showed at least
one (CA)16 allele. No correlation was found between intron 1
polymorphism and sex, smoking status, toxicity and other
biologic factors (Table 4).
EGFR intron 1 polymorphism showed a statistically
significant correlation with gefitinib activity; in fact, 25% of
patients with a (CA)16 genotype had an objective response, as
opposed to none of the patients with a (CA)else genotype
(odds ratio  10.7, 95% confidence interval 1.21–1415; p 
0.044) (Table 2). The effect of the (CA)16 genotype was
confirmed in the multivariate model including gender, smok-
ing status, EGFR intron 1 genotype and development of
toxicity during treatment (odds ratio  10.1, 95% confidence
interval 0.88–1475; p  0.07).
It was of note that patients bearing a (CA)16 genotype
showed a longer survival compared with those with a (CA)else
genotype (11.4 versus 4.8 months, respectively; hazard ratio
[HR] 0.49, 95% confidence interval 0.25–0.97; p  0.037)
(Figure 1). When gender, smoking status, histology, EGFR
intron 1 genotype and development of toxicity during treat-
TABLE 1. Patient Characteristics
No. of Patients (n  58) %
Gender
Males 39 67
Females 19 33
Age, years
Median (range) 67 (44–82)
Histology
Adenocarcinoma 43 74
Nonadenocarcinoma 15 26
Stage
IV 58 100
PS ECOG
0 14 24
1 36 62
2 8 14
Smoking status
Current or former smokers 47 81
No smokers 11 19
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ment were introduced in the multivariate model the effect of
the (CA)16 genotype on OS did not change (HR  0.55, 95%
confidence interval 0.27–1.15; p  0.111).
To confirm the predictive effect of EGFR intron 1
polymorphism we examined the outcomes of an additional
control cohort of NSCLC patients well balanced for each of
the clinical characteristics who did not receive gefitinib treat-
ment but only standard chemotherapy. In this control group
of 31 NSCLC patients no statistically significant differences
were seen in response rate and in overall survival of patients
classified according (CA)n genotype. In fact, 29.2% of pa-
tients (17/24) with a (CA)16 genotype and 28.6% of patients
(2/7) with a (CA)else genotype had an objective response (p 
1); moreover, no survival difference was observed between
these groups (12.4 versus 9.3 months, respectively; p 
0.558).
EGFR Gene Mutations, Gene Copy Number
and IHC Expression
EGFR gene mutational analysis was performed on 21
patients for whom paraffin embedded blocks were available.
Five heterozygous mutations were observed; all these muta-
tions have previously been described [four exon 19 deletions
(two 2235del15, one 2240del12 and one 2240del18) and one
TABLE 2. General Characteristics, EGFR Intron 1 Polymorphism, EGFR Gene Mutations, EGFR Gene Copy Number and
Immunohistochemistry Protein Expression in Gefitinib Responder and Nonresponder Patients
Characteristics
CR  PR
n (%)
SD  PD
n (%) p
DC
n (%)
PD
n (%) p
Median Survival
(Months) p
Sex 0.047 0.151 0.245
Female 6 (32) 13 (68) 10 (53) 9 (47) 8.4
Male 3 (8) 36 (92) 12 (31) 27 (69) 5.3
Smoking status 0.056 0.302 0.064
No smokers 4 (36) 7 (64) 6 (55) 5 (45) 12.7
Current or former 5 (11) 42 (89) 16 (34) 31 (66) 5.3
Histology 0.422 0.128 0.001
Adenocarcinoma 8 (19) 35 (81) 19 (44) 24 (56) 8.4
Nonadenocarcinoma 1 (7) 14 (93) 3 (20) 12 (80) 2.8
Toxicity 0.025 0.003 0.002
Yes 8 (28) 21 (72) 17 (59) 12 (41) 12
No 1 (3) 28 (97) 5 (17) 24 (83) 2.8
Skin toxicity 0.142 0.013 0.026
Yes 6 (25) 18 (75) 14 (58) 10 (42) 11.4
No 3 (9) 31 (91) 8 (23) 26 (77) 4.8
EGFR intron 1
polymorphism
0.044 0.004 0.037
(CA)16 genotype 9 (25) 27 (75) 19 (53) 17 (47) 11.4
(CA)else genotype 0 (0) 15 (100) 1 (7) 14 (93) 4.8
EGFR gene mutations 0.001 0.035 0.544
Mutated 5 (100) 0 (0) 5 (100) 0 (0) 18.5
Wild-type 1 (6) 15 (94) 6 (37) 10 (63) 8.8
EGFR FISH 0.326 0.630 0.179
Positive 3 (43) 4 (57) 4 (57) 3 (43) 8.8
Negative 2 (18) 9 (82) 4 (36) 7 (64) 18.5
EGFR IHC 0.530 0.582 0.436
Positive 5 (31) 11 (69) 7 (44) 9 (56) 5.7
Negative 0 (0) 3 (100) 2 (67) 1 (33) 17.3
p-EGFR IHC 0.278 0.314 0.221
Positive 0 (0) 5 (100) 1 (20) 4 (80) 5.1
Negative 4 (31) 9 (69) 7 (54) 6 (46) 18.5
p-MAPK IHC 0.608 0.188 0.892
Positive 3 (37) 5 (63) 6 (75) 2 (25) 8.8
Negative 2 (20) 8 (80) 4 (40) 6 (60) 5.1
p-AKT IHC 0.548 0.624 0.863
Positive 2 (40) 3 (60) 3 (60) 2 (40) 12.9
Negative 3 (18) 13 (82) 6 (41) 10 (59) 8.8
Percentage along each row.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DC, disease Control, CR  PR  SD; FISH, fluorescence in situ hybridization; IHC,
immunohistochemistry.
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exon 21 missense mutation (L858R)].18–20 All EGFR mutated
patients had an objective response to gefitinib. Among re-
sponders 5/6 (83%) showed EGFR gene mutation, while none
with stable or progressive disease did (p  0.001). EGFR
mutated patients evidenced a median survival of 18.5 months
compared with 8.8 months of EGFR wild type ones (p 
0.544) (Table 2).
EGFR FISH analysis was performed on 18 tumors
specimens and was positive in seven patients (38.9%). FISH
analysis demonstrated polysomy or amplification of EGFR
gene in 60% of responding patients. The differences between
responders and nonresponders were not statistically signifi-
cant and, moreover, no difference was observed in median
survival according FISH status (Table 2).
The IHC expression of EGFR, p-EGFR, p-MAPK and
p-AKT was assessed in the tumor specimens of 21 patients.
EGFR was positive in 84%, p-EGFR in 28%, p-MAPK in
44% and p-AKT in 23% of patients. Clinical response to
gefitinib and survival did not differ according to protein
expression of any of the biomarkers assessed (Table 2).
Sensitivity of NSCLC Cell Lines to Gefitinib
According to EGFR Intron 1 Polymorphism
After characterization of EGFR (CA)n polymorphism,
five NSCLC cell lines were classified as bearing a (CA)16
genotype [(CA)16–16: A549, SKMES-1 and H460; (CA)16–17:
H1299; (CA)16–18: Calu-3], whereas two as carrying a (CA)else
genotype [(CA)18–21: H1650; (CA)20–20: SKLU-1].
Figure 2 shows that after exposure to gefitinib, cell
lines with a (CA)else genotype displayed a reduced growth
inhibition compared with those with a (CA)16 genotype (on
average, IC50 values of 19.20  2.26 M versus 5.85  3.22
M, respectively; p  0.003). We considered resistant cell
lines showing IC50 10 M accordingly to other previously
published papers.15,25
DISCUSSION
The purpose of this study was to assess the possible
relationship between EGFR intron 1 polymorphism and the
outcome of gefitinib treatment in patients with advanced
NSCLC.
In this specific intron of the EGFR gene, a highly
polymorphic (CA)n repeat was identified. Recent in vitro and
in vivo studies indicate that transcriptional activity of EGFR
gene is related to the number of CA repeats in intron 1.9,15,26,27
As potential consequence, the response to EGFR TKIs may
differ between patients as a function of their genotype. This
finding is in line with the observation that skin toxicity during
gefitinib or erlotinib therapy is related to antitumor response28
supporting the hypothesis that sensitivity to EGFR TKI treat-
ment could be influenced not only by different levels of target
TABLE 3. Genotype and Allele Frequencies of EGFR Intron
1 Polymorphism in 51 Patients
Genotypes
(CA)n Repeats n (%)
Alleles
(CA)n Repeats n (%)
14–15 1 (2) 14 2 (2)
14–21 1 (2) 15 4 (3.9)
15–17 1 (2) 16 51 (50.0)
15–20 1 (2) 17 8 (7.8)
15–21 1 (2) 18 15 (14.7)
16–16 15 (29.4) 19 3 (2.9)
16–17 5 (9.8) 20 14 (13.7)
16–18 7 (13.7) 21 5 (4.9)
16–19 1 (2)
16–20 6 (11.8)
16–21 2 (3.9)
17–18 2 (3.9)
18–18 1 (2)
18–19 1 (2)
18–20 3 (5.9)
19–21 1 (2)
20–20 2 (3.9)
TABLE 4. Baseline Characteristics According to EGFR Intron
1 Polymorphism (CA)16 Genotype Versus (CA)else Genotype
(CA)16
Genotype
n (%)
(CA)else
Genotype
n (%) p
Gender 0.060
Males 21 (62) 13 (38)
Females 15 (88) 2 (12)
Smoking status 0.472
Current or former smokers 27 (67) 13 (33)
No smokers 9 (82) 2 (18)
Histology 0.083
Adenocarcinoma 29 (78) 8 (22)
Nonadenocarcinoma 7 (50) 7 (50)
Toxicity 0.759
Yes 20 (74) 7 (26)
No 16 (67) 8 (33)
Skin toxicity 0.554
Yes 18 (75) 6 (25)
No 18 (67) 9 (33)
EGFR gene mutations 0.260
Mutated 5 (100) 0 (0)
Wild-type 9 (60) 6 (40)
EGFR FISH 1
Positive 8 (67) 4 (33)
Negative 3 (60) 2 (40)
EGFR IHC 0.515
Positive 9 (60) 6 (40)
Negative 2 (100) 0 (0)
p-EGFR IHC 0.117
Positive 2 (40) 3 (60)
Negative 10 (83) 2 (17)
p-MAPK IHC 0.308
Positive 6 (85) 1 (15)
Negative 5 (56) 4 (44)
p-AKT IHC 0.260
Positive 5 (100) 0 (0)
Negative 9 (60) 6 (40)
Percentage along each row.
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
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expression in the tumor, but also by some inherited genetic
factor in the host.
Our study evidence a potential role of EGFR intron 1
polymorphism in predicting the outcome of gefitinib treat-
ment in advanced NSCLC, confirming the previous observa-
tion performed recently.29–31 Indeed, we observed that pa-
tients lacking the (CA)16 allele almost universally experience
rapid disease progression despite gefitinib treatment, suggest-
ing a possible negative predictive value of (CA)16 allele
absence in the response to EGFR TKI therapy. In addition,
patients with at least one (CA)16 allele [i.e., with (CA)16
genotype] had a longer survival than those lacking the (CA)16
allele [i.e., with (CA)else genotype].
It could be argued that (CA)16 genotype is just another
prognostic factor with the ability to confer a better prognosis
regardless of treatment. However, the only study (Eastern
Cooperative Oncology Group 3590) where the pure prognos-
tic value of this polymorphism was assessed came to the
opposite conclusion.32 In fact, this trial, a randomized pro-
spective study of adjuvant therapy following resection of
stage II–IIIA NSCLC, evidenced a prognostic significance of
EGFR intron 1 polymorphism, demonstrating that patients
with more than 35 (CA)n repeats, calculated as sum of the two
allele lengths, had a significantly longer overall survival
compared with patients with 35 or fewer (CA)n repeats.
Therefore, in this study longer EGFR intron 1 simple se-
quence repeats, evaluated in surgical specimens of patients
not treated with EGFR TKIs, are associated with improved
survival.
In addition, the lack of either predictive or prognostic
effect of (CA)16 genotype in the control gefitinib-untreated group
of our study provides further evidence that improved survival in
patients with (CA)16 genotype is due to improved efficacy of
gefitinib in this group. Therefore, the improved survival
found in our study for patients bearing a shorter allele length
was attributed to a higher efficacy of gefitinib in this group of
patients.
Our in vitro studies were consistent with this hypothe-
sis. In fact, NSCLC cell lines lacking the (CA)16 allele
demonstrated a statistically significant higher IC50 compared
with lines bearing at least one (CA)16 allele.
The most obvious mechanism by which this polymor-
phism is associated with gefitinib response is by affecting the
levels of EGFR, with an inverse correlation between the
number of intron 1 CA dinucleotides and protein expression,
which is known to influence efficacy of EGFR TKIs.21,33 This
inverse correlation has been noted in preclinical models,15
although in clinical studies, including our own, results are
less clear-cut.
It should be borne in mind that tumors may have other
somatic genetic alterations, such as the EGFR gene muta-
tions, EGFR gene amplification and also amplifications in
intron 1 region,9,34 which can compensate for the deficient
transcriptional activity of long alleles or suppress those of
short alleles. In this study, we confirmed significant clinical
benefit of gefitinib in patients with EGFR mutations, but not
FIGURE 1. Kaplan-Meier plot of survival
time according to EGFR intron 1 polymor-
phism. [(CA)16 genotype versus (CA)else geno-
type; HR  0.49, 95% confidence interval
0.25–0.97; p  0.037].
FIGURE 2. Distribution of IC50 values among NSCLC cell
lines classified for the EGFR intron 1 polymorphism. Cells were
treated with gefitinib concentrations ranging from 0.1 to 50
M for 72 hours and then cell viability was determined by
MTT assay as described in section “Patients and Methods.”
Representative results of at least 3 independent experiments.
[(CA)16 genotype versus (CA)else genotype, on average, IC50
values of 5.85  3.22 M versus 19.20  2.26 M, respec-
tively; p  0.003]. n  number of CA repeats.
Journal of Thoracic Oncology • Volume 3, Number 10, October 2008 Gefitinib Outcome in Advanced NSCLC
Copyright © 2008 by the International Association for the Study of Lung Cancer 1109
the predictive significance of EGFR gene copy number,
probably due to small number of cases. In our series, all
EGFR gene mutations were found in patients with (CA)16
allele as opposed to none in patients with (CA)else genotype,
although this difference was not statistically significant. A
similar lack of statistically significant correlation between
EGFR mutations and intron 1 polymorphism was found in the
only other reported study on this subject.35
In line with the hypothesis of a genetic predisposition
affecting a differential sensitivity to EGFR TKIs, we found a
predictive role for general toxicity and a survival advantage
for patients who developed adverse events, particularly skin
toxicity. We did not observe any correlation between (CA)n
repeat polymorphism and toxicity and the only other study
assessing this issue came to the same conclusions.36 Other
genetic factors, such as ABCG2 and ABCB1 polymor-
phisms,36 could account for the correlation between toxicity
and response to EGFR TKIs.
From a practical perspective, assessment of intron 1 poly-
morphism as a predictor for clinical outcome is attractive. It can
be easily measured in normal tissues, is a constant feature and is
technically simple, objective and quantitative in both fresh-
frozen and formalin-fixed, paraffin-embedded tissue.
Despite the small sample size and the lack histologic
material for correlative studies in most of them, our study
constitutes a starting point for elucidating the molecular basis
of genotypic differences in response to EGFR inhibitors. It
should also be emphasized that other polymorphisms in
linkage disequilibrium with the (CA)n repeat may also con-
tribute to variability in EGFR expression and to treatment
response. In conclusion, in addition to known gefitinib pre-
dictive factors, our data suggest a potential role of EGFR
intron 1 polymorphism in predicting response to gefitinib in
advanced NSCLC. Further prospective and larger studies in
the field are warranted.
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